JO
ABVC icon

John Overdeck’s ABVC BioPharma ABVC Stock Holding History

John Overdeck’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,210
Closed -$11.5K – 2929
2023
Q2 		$11.5K Sell
2,210
-280
-11% -$1.86K ﹤0.01% 2940
2023
Q1 		$15.9K Buy
+2,490
New +$17.8K ﹤0.01% 2864

Other funds holding ABVC

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

John Overdeck's ABVC Position: Q3 2023 in Review

John Overdeck sold out of ABVC BioPharma (ABVC) in Q3 2023, closing a stake of 2,210 shares — an estimated $11.5K sold.

John Overdeck first reported a position in ABVC in Q1 2023 and held it in 2 quarters. The position peaked at $15.9K in Q1 2023. 9 funds tracked by Wall St. Rank hold ABVC as of Q3 2023.

  • John Overdeck reported no remaining ABVC BioPharma position as of Q3 2023 after selling out during the quarter.
  • John Overdeck sold 2,210 ABVC BioPharma shares in Q3 2023, an estimated $11.5K.
  • John Overdeck first reported a position in ABVC BioPharma in Q1 2023 and held it in 2 quarters.
  • John Overdeck's ABVC BioPharma position peaked at $15.9K in Q1 2023.
  • 9 funds tracked by Wall St. Rank held ABVC BioPharma as of Q3 2023.

Based on Two Sigma Investments's 13F filing for Q3 2023, filed 14 Nov 2023.